Icariin: Multi-target natural products for the multi-stage prevention and treatment of breast cancer (Review).
AI Summary
Key Findings
Abstract
The present review examines the intricate relationship between icariin and breast cancer (BC), encompassing foundational theoretical concepts, epidemiological data, diagnostic methodologies, therapeutic approaches, ongoing debates and prospective future developments. The foundational theoretical concepts address the mechanisms through which icariin influences BC pathogenesis, as well as its pharmacokinetic and pharmacodynamic properties and historical context. The epidemiological section analyzes the global incidence and prevalence of BC, alongside its underlying pathophysiology. Diagnostic methodologies are discussed with a focus on imaging technologies, biomarkers, and the innovative role of icariin in advancing diagnostic techniques. Therapeutic approaches investigate icariin's potential as a chemo-preventive agent, its synergistic interactions with conventional therapies and the outcomes of clinical trials. The section on controversies explores discussions surrounding icariin's efficacy, safety and the associated regulatory and ethical considerations. Future directions emphasize emerging trends, the potential for personalized medicine, and future prospects in BC treatment. The present review aims to offer a comprehensive understanding of icariin's role in BC research and therapeutic applications.
Affiliation
Yu Wen
External References
- PubMed ID:
- 42147138
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.